GSK Vaccine Sales Hit By COVID-19 But Initial Signs Of Recovery
Group Sales Down 3% As UK Vaccine Supply Deal Is Struck
GlaxoSmithKline sees initial signs of recovery from the coronavirus pandemic in terms of vaccination rates and highlights its growing research progress against COVID, RSV and meningitis, although a UK expert warns against over-optimism.
